BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

Stocks like CIE Automotive India, Sanofi Consumer Healthcare, Delta Corp, Mahindra and Mahindra, Grindwell Norton, Keystone ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

Bernstein analyst Florent Cespedes maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €114.00. The ...

The FDA granted orphan designation to Sanofi US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Discover th ...

BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...

All information is at 31 January 2025 and unaudited.Performance at month end with net income reinvested ...

Sonoco’s competition is abundant, with competitors varying in size from larger packaging conglomerates to regional producers with expertise in particular products and end markets. While there are some ...

Approved final Dividend of Rs. 55 per equity share having the face value of Rs. 10 /- each for the Financial Year ended 31st December, 2024 ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

2-Year U.S. Treasury Note Continuous Contract $102.766 0.027 0.03% 5-Year U.S. Treasury Note Continuous Contract $106.461 0.102 0.10% 10-Year U.S. Treasury Note Continuous Contract $109.094 0.141 ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.